Wallin I - Search Results

1

Risk factors for cardiovascular disease during the period 1985-1995 in Göteborg, Sweden. The GOT-MONICA Project.

Wilhelmsen L, Johansson S, Rosengren A, Wallin I, Dotevall A, Lappas G. Wilhelmsen L, et al. Among authors: wallin i. J Intern Med. 1997 Sep;242(3):199-211. doi: 10.1046/j.1365-2796.1997.00163.x. J Intern Med. 1997. PMID: 9350164 Free article.

2

[A new risk pattern of coronary disease is alarming. Increased body weight threatens the positive trend].

Wilhelmsen L, Johansson S, Rosengren A, Wallin I, Dotevall A, Lappas G. Wilhelmsen L, et al. Among authors: wallin i. Lakartidningen. 1998 Sep 9;95(37):3966-70. Lakartidningen. 1998. PMID: 9772783 Swedish. No abstract available.

3

GP and patient predictions of sick-listing duration: how well do they correspond? A prospective observational study.

Ericson Sjöström M, Wallin I, Strandhagen E, Baigi A, Hensing G, Björkelund C. Ericson Sjöström M, et al. Among authors: wallin i. Scand J Prim Health Care. 2014 Jun;32(2):73-7. doi: 10.3109/02813432.2014.915132. Scand J Prim Health Care. 2014. PMID: 24939740 Free PMC article.

4

Busulfan bioavailability.

Hassan M, Ljungman P, Bolme P, Ringdén O, Syrůcková Z, Békàssy A, Starý J, Wallin I, Kållberg N. Hassan M, et al. Among authors: wallin i. Blood. 1994 Oct 1;84(7):2144-50. Blood. 1994. PMID: 7919328 Free article.

5

Oral melphalan pharmacokinetics: influence of interferon-induced fever.

Ehrsson H, Eksborg S, Wallin I, Osterborg A, Mellstedt H. Ehrsson H, et al. Among authors: wallin i. Clin Pharmacol Ther. 1990 Jan;47(1):86-90. doi: 10.1038/clpt.1990.13. Clin Pharmacol Ther. 1990. PMID: 2295223 Clinical Trial.

6

Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology.

Hassan M, Oberg G, Bekassy AN, Aschan J, Ehrsson H, Ljungman P, Lönnerholm G, Smedmyr B, Taube A, Wallin I, et al. Hassan M, et al. Among authors: wallin i. Cancer Chemother Pharmacol. 1991;28(2):130-4. doi: 10.1007/BF00689702. Cancer Chemother Pharmacol. 1991. PMID: 2060084

7

Cerebrospinal fluid and plasma concentrations of busulfan during high-dose therapy.

Hassan M, Ehrsson H, Smedmyr B, Tötterman T, Wallin I, Oberg G, Simonsson B. Hassan M, et al. Among authors: wallin i. Bone Marrow Transplant. 1989 Jan;4(1):113-4. Bone Marrow Transplant. 1989. PMID: 2647175

8

Pharmacokinetic and metabolic studies of busulfan in rat plasma and brain.

Hassan M, Ehrsson H, Wallin I, Eksborg S. Hassan M, et al. Among authors: wallin i. Eur J Drug Metab Pharmacokinet. 1988 Oct-Dec;13(4):301-5. doi: 10.1007/BF03190094. Eur J Drug Metab Pharmacokinet. 1988. PMID: 3243326

9

Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics.

Hassan M, Oberg G, Björkholm M, Wallin I, Lindgren M. Hassan M, et al. Among authors: wallin i. Cancer Chemother Pharmacol. 1993;33(3):181-6. doi: 10.1007/BF00686213. Cancer Chemother Pharmacol. 1993. PMID: 8269597

10

Pharmacokinetic and metabolic studies of high-dose busulphan in adults.

Hassan M, Oberg G, Ehrsson H, Ehrnebo M, Wallin I, Smedmyr B, Tötterman T, Eksborg S, Simonsson B. Hassan M, et al. Among authors: wallin i. Eur J Clin Pharmacol. 1989;36(5):525-30. doi: 10.1007/BF00558081. Eur J Clin Pharmacol. 1989. PMID: 2753072

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

58 results

Search Page

Filters